- Home
- NBP vs DSGN Comparison
NBP vs DSGN Comparison
Compare NBP & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NBP | DSGN |
|---|---|---|
| Founded | 2014 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 503.8M | 579.9M |
| IPO Year | 2020 | 2021 |
Fundamental Metrics
Financial Performance| Metric | NBP | DSGN |
|---|---|---|
| Price | $3.27 | $10.27 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $15.00 |
| AVG Volume (30 Days) | ★ 989.3K | 307.0K |
| Earning Date | 04-01-2026 | 03-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.60 | $2.60 |
| 52 Week High | $6.79 | $10.97 |
Technical Indicators
Market Signals| Indicator | NBP | DSGN |
|---|---|---|
| Relative Strength Index (RSI) | 34.33 | 55.81 |
| Support Level | $3.71 | $9.66 |
| Resistance Level | $4.08 | $10.81 |
| Average True Range (ATR) | 0.29 | 0.76 |
| MACD | -0.03 | 0.05 |
| Stochastic Oscillator | 2.38 | 67.44 |
Price Performance
Historical ComparisonAbout NBP NovaBridge Biosciences American Depositary Shares
NovaBridge Biosciences operates as a biotechnology platform, combining business development and clinical research to identify and advance pharmaceutical assets. It integrates scientific discovery with strategic planning and project management to move therapies from research toward potential patient use. Its pipeline includes Givastomig, VIS-101, Ragistomig and Uliledlimab.
About DSGN Design Therapeutics Inc.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.